Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778626 | 1.00 | CTSS (0.44) | CTSSCTSKSLC7A5ITGB3ITGA2B | |
| SCHEMBL6661008 | 1.00 | CTSS (0.44) | CTSSCTSKSLC7A5ITGB3ITGA2B | |
| SCHEMBL25173080 | 0.89 | PPARG (0.40) | SLC7A5ITGB3ITGA2BMMP13REN | |
| SCHEMBL65502 | 0.89 | MMP13 (0.46) | CTSSCTSKSLC7A5ITGB3ITGA2B | |
| SCHEMBL1401042 | 0.89 | MMP13 (0.46) | CTSSCTSKSLC7A5ITGB3ITGA2B | |
| SCHEMBL2476924 | 0.89 | MMP13 (0.46) | CTSSCTSKSLC7A5ITGB3ITGA2B | |
| SCHEMBL1401163 | 0.88 | CTSS (0.46) | CTSSCTSKITGB3ITGA2BMMP13 | |
| SCHEMBL7855989 | 0.88 | ADORA1 (0.40) | CTSSCTSKSLC7A5ITGB3ITGA2B | |
| SCHEMBL20585552 | 0.88 | TP53 (0.40) | ITGB3ITGA2BMMP13RENADORA1 | |
| SCHEMBL7248901 | 0.88 | CTSS (0.46) | CTSSCTSKITGB3ITGA2BMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0624599-B1 | Derivatives of mono (6-amino-desoxy)cyclodextrin substituted in position 6 with an alpha aminoacid group, process of their preparation and applications | OREAL (FR) | 1997-07-30 | — | — | EP | claimed |
| US-20260077069-A1 | COMBINATIONS OF CONTRAST AGENTS | BAYER AG (DE) | 2026-03-19 | — | — | US | disclosed |
| EP-4584251-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4583925-A1 | COMBINATIONS OF CONTRAST AGENTS | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052573-A1 | COMBINATIONS OF CONTRAST AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024052549-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| EP-4335840-A1 | NEW CONTRAST AGENTS FOR USE IN DIAGNOSTIC IMAGING | Bayer Aktiengesellschaft (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4335461-A1 | COMBINATIONS OF CONTRAST AGENTS | Bayer AG (DE) | 2024-03-13 | — | — | EP | disclosed |
| CN-109912683-B | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-115505029-A | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-5216150-A | Muscle relaxant; enzyme inhibitor and platelet aggutination inhibitor | Hidaka, Hiroyoshi (JP) | 1993-06-01 | — | — | US | disclosed |
| US-5081246-A | Isoquinolino sulfonamino derivatives | Hidaka, Hiroyoshi (JP) | 1992-01-14 | — | — | US | disclosed |
| CN-1044098-A | Compounds with vascular smooth muscle relaxing activity | HIDAKA HIROYOSHI (JP) | 1990-07-25 | — | — | CN | disclosed |
| EP-0081838-B1 | CYCLOHEXYL AND PHENYL SUBSTITUTED ENKEPHALINS | G.D. Searle & Co. (US) | 1988-04-27 | — | — | EP | disclosed |
| US-4722922-A | RENIN INHIBITION | G. D. SEARLE & CO. (US) | 1988-02-02 | — | — | US | disclosed |
| US-4603121-A | ANALGESICS | G. D. SEARLE & CO. (US) | 1986-07-29 | — | — | US | disclosed |
| EP-0136720-A2 | Enkephalin analogs | G.D. Searle & Co. (US) | 1985-04-10 | — | — | EP | disclosed |
| US-4495178-A | Enkephalin analogs | G. D. SEARLE & CO. (US) | 1985-01-22 | — | — | US | disclosed |
| US-4407746-A | Cyclohexyl and phenyl substituted enkephalins | G. D. SEARLE & CO. (US) | 1983-10-04 | — | — | US | disclosed |
| EP-0081838-A1 | Cyclohexyl and phenyl substituted enkephalins | G.D. Searle & Co. (US) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077069-A1 | COMBINATIONS OF CONTRAST AGENTS | GBA1, GBA3, GLS2 | CTSS 386/4885CTSK 1543/4885SLC7A5 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.